Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
about
Burden of Gastrointestinal and Liver Diseases in Middle East and North Africa: Results of Global Burden of Diseases Study from 1990 to 2010Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C.Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseEstimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Economic evaluation of HCV testing approaches in low and middle income countries.Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions.Approaches for simplified HCV diagnostic algorithms.Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt's hepatocellular cancer epidemic: simulation of alternatives.Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based EvidenceHepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries
P2860
Q27000368-47B67A46-B1A7-4B7E-B632-11BD530C2F25Q35934655-5B56EE11-6B66-4FE3-9577-B7E6C3A2F4DAQ36168072-BE19B82C-B9AD-44B0-98CE-725A5588745FQ36240269-EE7139AF-EF7B-4186-BFCB-5A1E9A2D4ACAQ36242517-83478564-2C4E-42C1-9BF1-88FDC579A780Q37251861-F63541B3-E18A-416F-A9C2-8F854CF0C651Q39047581-2CEADB27-9FD8-437A-976E-7B8878B7E15DQ42048758-AFD9A717-FBE6-452B-AD25-928997022A60Q46983780-09CEEE7E-5416-4047-8022-C7ED29F45116Q47548612-553820B3-4D45-4005-AE55-A681A66084D0Q52597014-85F231A8-438E-4F57-BA9C-9CA4A096FFE8Q53688288-831D202F-781A-42BB-8993-70DB01A3AA90Q57145115-48EE36FF-098D-4DD2-8AEA-054E623D72B1Q57153229-F0BB5942-D48A-4CF5-B230-2FB5AE314BA7
P2860
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cost-effectiveness model for h ...... ountries with high prevalence.
@ast
Cost-effectiveness model for h ...... ountries with high prevalence.
@en
type
label
Cost-effectiveness model for h ...... ountries with high prevalence.
@ast
Cost-effectiveness model for h ...... ountries with high prevalence.
@en
prefLabel
Cost-effectiveness model for h ...... ountries with high prevalence.
@ast
Cost-effectiveness model for h ...... ountries with high prevalence.
@en
P2093
P2860
P1433
P1476
Cost-effectiveness model for h ...... ountries with high prevalence.
@en
P2093
Ahmed A Raouf
Ahmed Hablas
Amr S Soliman
David W Hutton
Ibrahim A Seifeldin
Mohsen Salama
P2860
P304
P356
10.1080/17441692.2014.984742
P50
P577
2014-12-03T00:00:00Z